Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

QualityMetric Offers Way To Measure The Impact Of Sleep Problems On Individuals And Groups
There are few things as vital to health and well-being as a good night"s sleep. Yet millions of us -- nearly 50 million according to the National Sleep Foundation -- suffer from chronic sleep problems or disorders. Every year, more and more scientific studies are showing correlations between poor or insufficient sleep and disease. Now there is a simple, easy way to quantify and measure sleep problems with patient populations.

Health Plans Support Consumer Protections
Health plans reiterated their strong support for new market rules and consumer protections to cover all Americans and guarantee coverage for pre-existing conditions.
News of the day
Today's Selection Of Opinions And Editorials
Comparative-Effectiveness Research - Implications of the Federal Coordinating Council"s Report The New England Journal Of Medicine
Cardiovascular

Medtronic's Corevalve Shows Subclavian Access Success In Patients Contraindicated For Femoral Approach

Medtronic, Inc. (NYSE: MDT) announced new data presented today on the safety and effectiveness of Medtronic"s CoreValve system via a novel, subclavian approach. The data reported procedural success of 100 percent; 24- hour survival of 100 percent; and 30-day survival of 89 percent. The available 30-day analysis also demonstrated clinical improvement in heart failure symptoms with 76 percent of the patients gaining at least a oneņ€stage NYHA class and oneņ€third improving by at least two stages. Medtronic"s marketņ€leading CoreValve system was designed to allow the implant of a replacement heart valve in patients with aortic stenosis who are at high or prohibitive surgical risk. The system enables a catheterņ€based implant via a peripheral blood vessel, traditionally the femoral artery. A significant subset of patients, however, have compromised peripheral arteries, which prevents the use of the femoral approach. Uniquely, the delivery system of the CoreValve device is small enough to allow an alternative approach via the subclavian artery beneath the collar bone. "The combination of unique valve design and controlled deliverability have contributed to the tremendous success of the Medtronic CoreValve system using the femoral approach," said John Liddicoat M.D., vice president and general manager of the CardioVascular Structural Heart division at Medtronic. "These new data suggest that a subclavian artery approach could address yet another underņ€served patient population. We are committed to gather the necessary clinical experience and evidence to support the routine use of a subclavian approach in those for whom a femoral approach is not possible." The data presented today at the PCR interventional cardiology meeting in Barcelona reported on data from 74 patients for whom subclavian access was used within the CoreValve Extended Evaluation Registry, an observational study which closed in January 2009. The average age of the patients was 81.4. Moreover, the average Logistic EuroSCORE (a measure which predicts risk of procedural mortality based upon patient status) was notably high at 28.4%. Medtronic


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009